Optimizing Post-allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using Ibrutinib
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma
- Focus Therapeutic Use
- 14 Oct 2016 Planned End Date changed from 1 Sep 2020 to 1 Oct 2020.
- 14 Oct 2016 Planned primary completion date changed from 1 Sep 2018 to 1 Oct 2018.
- 14 Oct 2016 Status changed from not yet recruiting to recruiting.